Triplet Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Triplet Therapeutics's estimated annual revenue is currently $1.2M per year.
- Triplet Therapeutics's estimated revenue per employee is $77,500
- Triplet Therapeutics's total funding is $59M.
Employee Data
- Triplet Therapeutics has 16 Employees.
- Triplet Therapeutics grew their employee count by -6% last year.
Triplet Therapeutics's People
| Name | Title | Email/Phone |
|---|
Triplet Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Triplet Therapeutics?
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntingtonￃﾢ￢ﾂﾬ￢ﾄﾢs disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.
keywords:N/A
$59M
Total Funding
16
Number of Employees
$1.2M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Triplet Therapeutics News
... demand for triplet-based therapies and increasing treatment duration. ... Bristol Myers and Nektar Therapeutics NKTR announced the joint...
Bermingham helped found Intellia Therapeutics, Korra Bio and Triplet Therapeutics. Age: 49. Education: Bachelor of science in genetics from...
... with their PD-1 inhibitor tislelizumab and a triplet using all 3. ... Digital Therapeutics can positively impact the trajectory of a...
Triplet Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company leveraging human genetics to develop treatments for repeat expansion disorders at their source, raised $59m in financing. This includes a $49m Series A financing led by MPM Capital and Pfizer Ventures U.S. LLC, the ventu ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.8M | 16 | -6% | N/A |
#2 | $2.5M | 16 | 7% | N/A |
#3 | $1.2M | 16 | -11% | $65M |
#4 | $1.9M | 16 | 0% | N/A |
#5 | $1.7M | 16 | 7% | N/A |